Medi-Exametazim

Exametazime, the active ingredient in Medi-Exametazim, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in diagnostic imaging to assess cerebral blood flow, supporting the evaluation of stroke, epilepsy, and brain tumors in patients undergoing single‑photon emission computed tomography (SPECT).

GNH USA supplies Medi-Exametazim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides the product under strict quality standards to meet the needs of imaging centres and clinical laboratories across global markets.

Medi-Exametazim is used in cerebral perfusion imaging to visualize blood flow dynamics in the brain. Cerebral perfusion imaging (SPECT): provides quantitative assessment of regional cerebral blood flow. Stroke evaluation: helps differentiate ischemic from hemorrhagic regions and assess tissue viability. Epilepsy assessment: identifies focal perfusion abnormalities associated with seizure foci. Brain tumor imaging: delineates tumor vascularity and perfusion characteristics for treatment planning.

Adverse reactions to Medi-Exametazim are generally related to the injection procedure and the radiopharmaceutical nature of the product.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Transient flushing: brief sensation of warmth or redness. - Nausea: mild, self‑limiting nausea after administration. - Headache: occasional mild headache. - Dizziness: temporary light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Severe hypotension: marked drop in blood pressure post‑injection. - Radiation‑induced skin injury: localized erythema or ulceration at high exposure sites.

Prior to using Medi-Exametazim, several safety considerations should be observed to minimize risk. - Verify radiochemical purity: confirm the product meets established quality specifications before administration. - Use only with technetium‑99m generator: ensure appropriate labeling procedure is followed. - Assess allergy history: screen patients for known hypersensitivity to radiopharmaceuticals or excipients. - Monitor vital signs: observe blood pressure, heart rate, and respiratory status during and after injection. - Avoid in pregnancy or breastfeeding unless essential: weigh diagnostic benefit against potential fetal or infant radiation exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Medi-Exametazim may interact with certain agents that affect radiopharmaceutical distribution or patient physiology.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: co‑administration can lead to competition for technetium‑99m binding sites and reduced image quality. - High‑dose iodine compounds: may interfere with technetium labeling efficiency.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of allergic reactions, requiring closer observation. - Beta‑blockers: can blunt cardiovascular responses, making hypotension harder to detect. - Diuretics: may alter plasma volume, affecting tracer distribution and image interpretation.